Blood test to monitor treatment in metastatic breast cancer
Using a Liquid Biopsy to Monitor Metastatic Breast Cancer Treatment
This study is testing a new blood test to see if it can help women with metastatic breast cancer know sooner if their treatment is working.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Queen's University Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Kingston, Ontario and 1 other locations) |
| Trial ID | NCT05804578 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of the mDETECT blood test in monitoring treatment responses in women with metastatic breast cancer. The mDETECT assay utilizes a liquid biopsy approach to detect specific DNA methylation patterns associated with breast cancer, allowing for earlier assessment of treatment efficacy compared to traditional imaging methods. By analyzing circulating tumor DNA from blood samples, the study seeks to provide timely insights into whether a patient's therapy is effective, potentially reducing delays in switching to more effective treatments. The study includes women with measurable metastatic breast cancer who are starting a new systemic therapy regimen.
Who should consider this trial
Good fit: Ideal candidates are adult women with a confirmed diagnosis of metastatic breast cancer who are starting a new systemic therapy.
Not a fit: Patients with exclusive bone metastases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enable earlier detection of treatment responses, leading to improved management of metastatic breast cancer.
How similar studies have performed: Other studies utilizing liquid biopsy approaches have shown promise in monitoring cancer treatment responses, suggesting potential success for this method.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria -Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent \[to be herein described as 'metastatic'\]
Where this trial is running
Kingston, Ontario and 1 other locations
- Kingston Health Sciences Centre - Cancer Centre of Southeastern Ontario — Kingston, Ontario, Canada (Recruiting)
- Sunnybrook Health Sciences Centre — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Christopher R Mueller, Ph.D. — Queen's University
- Study coordinator: Christopher R Mueller, Ph.D.
- Email: muellerc@queensu.ca
- Phone: 613-533-6751
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.